Teva will have to endure revenue 'trough' in 2019

quickly. However, both face competition in the marketplace, and Teva doesn’t have much in the late-stage pipeline to provide additional options. ... Meanwhile, Austedo competes with a drug from Neurocrine Biosciences called Ingrezza (valbenazine), and

Havas Lynx Group scoops nine Golds at PM Society Awards

Other Gold winners included Aspen, Boeringher Ingelheim, Galderma, Johnson &Johnson, Mundipharma, Napp, Novartis, PTC Therapeutics, Shire, Teva, Tillotts Pharma and ViiV. ... Craft Award for Interactive Communications: Havas Lynx for Teva Pharmaceuticals.

Pfizer closes on EU approval of lung cancer drug Vizimpro

The CHMP also backed Teva’s CGRP inhibitor Ajovy (fremanezumab) for migraine prevention, setting the drug on course to compete with earlier approvals Aimovig (erenumab) from Amgen/Novartis and Emgality (galcanezumab)

GSK’s Advair Diskus faces first generic in US

Teva won approval for its AirDuo product last year in the US, providing the same active ingredients as Advair but with a lower dose of salmeterol which means it is not ... At the same time, Teva also launched an authorised generic of its own brand to try

1 2 3 4 5 6 7 8 9 10 [ Next 5 results ]